Literature DB >> 22360627

Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.

B N Yamaja Setty1, Nigel S Key, A Koneti Rao, Suhita Gayen-Betal, Suba Krishnan, Carlton D Dampier, Marie J Stuart.   

Abstract

Tissue Factor (TF) initiates thrombin generation, and whole blood TF (WBTF) is elevated in sickle cell disease (SCD). We sought to identify the presence of TF-positive monocytes in SCD and their relationship with the other coagulation markers including WBTF, microparticle-associated TF, thrombin-antithrombin (TAT) complexes and D-dimer. Whether major SCD-related pathobiological processes, including haemolysis, inflammation and endothelial activation, contribute to the coagulation abnormalities was also studied. The cohort comprised children with SCD (18 HbSS, 12 HbSC, mean age 3·6 years). We demonstrated elevated levels of TF-positive monocytes in HbSS, which correlated with WBTF, TAT and D-dimer (P = 0·02 to P = 0·0003). While TF-positive monocytes, WBTF, TAT and D-dimer correlated with several biomarkers of haemolysis, inflammation and endothelial activation in univariate analyses, in multiple regression models the haemolytic markers (reticulocytes and lactate dehydrogenase) contributed exclusively to the association with all four coagulant markers evaluated. The demonstration that haemolysis is the predominant operative pathology in the associated perturbations of coagulation in HbSS at a young age provides additional evidence for the early use of therapeutic agents, such as hydroxycarbamide to reduce the haemolytic component of this disease.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360627      PMCID: PMC3323750          DOI: 10.1111/j.1365-2141.2012.09065.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  40 in total

1.  Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice.

Authors:  D K Kaul; R P Hebbel
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease.

Authors:  Armand Mekontso Dessap; Jean-François Deux; Nour Abidi; Cécile Lavenu-Bombled; Giovanna Melica; Bertrand Renaud; Bertrand Godeau; Serge Adnot; Laurent Brochard; Christian Brun-Buisson; Frederic Galacteros; Alain Rahmouni; Anoosha Habibi; Bernard Maitre
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

Review 3.  Tissue factor and its measurement in whole blood, plasma, and microparticles.

Authors:  Nigel S Key; Nigel Mackman
Journal:  Semin Thromb Hemost       Date:  2010-11-03       Impact factor: 4.180

Review 4.  Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.

Authors:  Robert P Hebbel
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

5.  Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity.

Authors:  R D Lee; D A Barcel; J C Williams; J G Wang; J C Boles; D A Manly; N S Key; N Mackman
Journal:  Thromb Res       Date:  2011-07-06       Impact factor: 3.944

6.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

Review 7.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

8.  Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.

Authors:  Suba Krishnan; Yamaja Setty; Suhita G Betal; Vaidyula Vijender; Koneti Rao; Carlton Dampier; Marie Stuart
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

9.  Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease.

Authors:  Eduard J van Beers; Marianne C L Schaap; René J Berckmans; Rienk Nieuwland; Augueste Sturk; Frederiek F van Doormaal; Joost C M Meijers; Bart J Biemond
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

10.  Association of coagulation activation with clinical complications in sickle cell disease.

Authors:  Kenneth I Ataga; Julia E Brittain; Payal Desai; Ryan May; Susan Jones; John Delaney; Dell Strayhorn; Alan Hinderliter; Nigel S Key
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

View more
  27 in total

1.  Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Pichika Chantrathammachart; Kasemsiri Chandarajoti; Nigel Mackman; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

Review 2.  Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.

Authors:  Eboni I Lance; James F Casella; Allen D Everett; Emily Barron-Casella
Journal:  Proteomics Clin Appl       Date:  2014-11-06       Impact factor: 3.494

3.  Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Pichika Chantrathammachart; Jacqueline Mickelson; Joanne van Ryn; Robert P Hebbel; Dougald M Monroe; Nigel Mackman; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

4.  Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.

Authors:  B N Yamaja Setty; Suhita Gayen Betal; Robin E Miller; Dawn S Brown; Maureen Meier; Michele Cahill; Norma B Lerner; Nataly Apollonsky; Marie J Stuart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2019-05-10       Impact factor: 4.006

5.  Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.

Authors:  Riten Kumar; Joseph Stanek; Susan Creary; Amy Dunn; Sarah H O'Brien
Journal:  Blood Adv       Date:  2018-02-13

6.  Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease.

Authors:  Raisa Balbuena-Merle; Susanna A Curtis; Lesley Devine; David R Gibb; Matthew S Karafin; Chance John Luckey; Christopher A Tormey; Alexa J Siddon; John D Roberts; Jeanne E Hendrickson
Journal:  Transfusion       Date:  2019-07-29       Impact factor: 3.157

Review 7.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 8.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 9.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

Review 10.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.